The document discusses efforts to improve neural tube defect (NTD) prevention in Scandinavian countries by rethinking folate strategies. It outlines roundtable meetings held with key opinion leaders, health authorities, and user organizations to establish consensus around implementing a new national folate policy. Political follow-up meetings were also conducted. Media coverage of the issue included editorials and TV segments. Next steps include further Scandinavian alignment, disseminating a new NTD report, and parliamentary seminars to push for better folate awareness campaigns.
The New Mental Health Strategy for England - Department of Health - Dr Hugh G...alexhobbs
Hot off the press, Dr Hugh Griffiths, National Clinical Director for Mental Health at Department of Health, shares the slides from his latest Healthcare Events presentation delivered yesterday on 24th May 2011.
Context, gender and sustainability in introducing and scaling-up essential he...ReBUILD for Resilience
Presented by Egbert Sondorp of KIT Royal Tropical Institute, Netherlands.
Part of a session - 'Context, gender and sustainability in introducing and scaling-up essential health care packages in fragile and crisis-affected countries' - at the Fifth Global Symposium for Health Systems Research in October 2018. The essential package of health services is a mechanism for expanding equitable coverage of primary health care and essential hospital services in countries recovering from conflict. The session explored the evidence-base on such healthcare packages in different contexts and prioritized areas for strengthening research.
presented by Zsuzsanna Jakab, WHO Regional Director for Europe on 18 November 2014 at Ministerial Meeting in Skopje, The former Yugoslav Republic of Macedonia
The New Mental Health Strategy for England - Department of Health - Dr Hugh G...alexhobbs
Hot off the press, Dr Hugh Griffiths, National Clinical Director for Mental Health at Department of Health, shares the slides from his latest Healthcare Events presentation delivered yesterday on 24th May 2011.
Context, gender and sustainability in introducing and scaling-up essential he...ReBUILD for Resilience
Presented by Egbert Sondorp of KIT Royal Tropical Institute, Netherlands.
Part of a session - 'Context, gender and sustainability in introducing and scaling-up essential health care packages in fragile and crisis-affected countries' - at the Fifth Global Symposium for Health Systems Research in October 2018. The essential package of health services is a mechanism for expanding equitable coverage of primary health care and essential hospital services in countries recovering from conflict. The session explored the evidence-base on such healthcare packages in different contexts and prioritized areas for strengthening research.
presented by Zsuzsanna Jakab, WHO Regional Director for Europe on 18 November 2014 at Ministerial Meeting in Skopje, The former Yugoslav Republic of Macedonia
United Nations Convention on the Rights of Persons with DisabilitiesIFsbh
IF workshop in the European Parliament in Strasbourg, October 2012. Dima Yared, Human Rights Officer at United Nations Office for Human Rights, Regional office for Europe, presented the United Nation Convention on the Rights of Persons with Disabilities and how to use it to advocate for and promote the rights to work of people with disabilities.
Discouragement is a personal and very pesky obstacle to service. In today’s message we will visit a Biblical hero who learned how to be delivered from discouragement.
This is a presentation that I gave to my graduate level Vitamins and Minerals class depicting how the amino acid homocysteine effects cardiovascular disease.
Workshop 7 - Brainstorming & Policy Development session: Prevention
"Folic acid prevents neural tubes defect"
Mrs Eli Skattebu, Norwegian Association for Spina Bifida and Hydrocephalus (RHF)"
Kim Hannisdal, BayerAB, Sweden
United Nations Convention on the Rights of Persons with DisabilitiesIFsbh
IF workshop in the European Parliament in Strasbourg, October 2012. Dima Yared, Human Rights Officer at United Nations Office for Human Rights, Regional office for Europe, presented the United Nation Convention on the Rights of Persons with Disabilities and how to use it to advocate for and promote the rights to work of people with disabilities.
Discouragement is a personal and very pesky obstacle to service. In today’s message we will visit a Biblical hero who learned how to be delivered from discouragement.
This is a presentation that I gave to my graduate level Vitamins and Minerals class depicting how the amino acid homocysteine effects cardiovascular disease.
Workshop 7 - Brainstorming & Policy Development session: Prevention
"Folic acid prevents neural tubes defect"
Mrs Eli Skattebu, Norwegian Association for Spina Bifida and Hydrocephalus (RHF)"
Kim Hannisdal, BayerAB, Sweden
The state in global health (focus on LICs/MICs)Albert Domingo
A report/presentation on the changing dynamics of the power of the state viz. external actors in formulating health policy, particularly in low income countries and middle income countries.
Working with/in Health Departments to Promote Harm Reduction: Cuellar, McLea...Harm Reduction Coalition
Larry Cuellar (Texas Department of State Health Services), Rachel McLean (California Department of Public Health), Emalie Huriaux, (San Francisco Department of Public Health), and Laura Thomas (Drug Policy Alliance) on harm reduction collaborations between community groups and health departments. Presented at the Harm Reduction Coalition's 8th National Conference, November 18-21, 2010 in Austin, Texas.
IF workshop at the European Parliament in Strasbourg, October 2012. Martin Künemund presented the project “We empower Us bh” to share knowledge and good examples to improve job opportunities for people with Spina Bifida and Hydrocephalus.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
1. “RETHINK FOLATE!”
Working with improved NTD prevention in the
Scandinavian countries
Eli D Skattebu, Norwegian association for Spina Bifida
and Hydrocephalus and Kim Hannisdal, Bayer
Healthcare Pharmaceuticals
2. Aim and target groups
• Objective
- Establish consensus among influential scientists, health- and nutritional
authorities and politicians that;
• Current folate strategies are not working
• The problem with NTDs persist
• We must consider new solutions for medical and ethical reasons
• Action based on new understanding
• Primary target groups
- Health authorities, scientific and clinical community, and
political environment
3. Timeline • Scandinavian
alignment
• Follow up, politics
and media
• Dissemination of
“Let us rethink folate!” new report as leverage
for new political dialogue
Dec 2009 – Jan 2010
Dec 2009 – Jan 2010 Jan 2010 – Aug 2011
• Round table meetings with:
•KOLs
•Health authorities
•User organizations
• Follow up with politicians
and the media
4. What we have done so far
• Round table meetings
• Follow up with politicians
• PR
5. Round table meetings I
• Purpose:
- Ascribe responsibility to the appropriate governmental body to
renew and implement a national policy for prevention of NTDs by
folate
- Platform for political initiatives aiming to:
• Political pressure for a new or strengthened policy
• Budget coverage for new information campaigns
6. Round table meetings II
• Meeting over four hours with the most relevant authorities and the
experts in the field
• Brief lectures from experts and authority representatives in an order
leading to a discussion on future policy and responsibilities for this
• Moderated by the former Minister of the Environment Guro
Fjellanger who has Spina Bifida her selves
• Hosted by the Norwegian association for Spina Bifida and
Hydrocephalus association and Bayer
7. Participants
• National Directorate of Health
• Experts;
- Epidemiologist with specific knowledge on incidence/prevalence
of NTDs
- Gynaecology
- Paediatrics
- Medical ethics
- Social medicine
8. Agenda in brief
• Welcome
• Situation report: Incidence and prevalence of NTDs
• Medical, social and ethical implications of today's practice for
prevention
• Experiences from existing prevention strategies
• Possible measures to be considered
• Next steps and who will be responsible
• Wrap up
9. Political follow up
• Contact with Health Ministers and the Standing Committees for
Health in the national parliament for meetings on;
- The need for new policy
- The need for political pressure on the authorities responsible
- The need for a new, state financed public campaign on folate
supplement in next year’s budget
10. Media coverage so far I
• 2010:
- Chronicle by Spina Bifida and Bayer on Rare Disease day in Norway.
• NTDs can be prevented with folate
• Current strategies are not working
• We will initiate a new dialogue on improving prevention strategies
with experts and authorities
- Article after the round table meeting and before political meetings:
• Special focus on ethical challenges by secondary prophylaxis
• Concluding with Spina Bifidas expectations on a policy change and a
public campaign.
13. Media coverage so far II
• 2011:
- Editorial in the Journal for the Norwegian Doctors’ Association,
January
• NTDs can be prevented
• Prevention potential by folate is not fully utilized
• New initiatives, e.g. awareness campaigns, are needed
- TV coverage two consecutive days, April
• Abortions as a secondary prevention strategy is unacceptable
• Need for better awareness campaigns
14.
15. Next steps
• Political follow up
• - Better Scandinavian alignment
- Pan-Scandinavian meeting, Brussels June 28th
• Dissemination of the second report on NTDs in Europe
- Scandinavian “Road show” with IFs President Pierre Mertens
• Seminars with health committees in the parliaments
• Meetings with health ministers, possible
• Media interviews